US20020006959A1 - Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism - Google Patents

Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism Download PDF

Info

Publication number
US20020006959A1
US20020006959A1 US09/845,741 US84574101A US2002006959A1 US 20020006959 A1 US20020006959 A1 US 20020006959A1 US 84574101 A US84574101 A US 84574101A US 2002006959 A1 US2002006959 A1 US 2002006959A1
Authority
US
United States
Prior art keywords
medium chain
alzheimer
camitine
chain triglycerides
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/845,741
Other languages
English (en)
Inventor
Samuel Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerecin Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22743976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020006959(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/845,741 priority Critical patent/US20020006959A1/en
Application filed by Individual filed Critical Individual
Publication of US20020006959A1 publication Critical patent/US20020006959A1/en
Priority to US10/152,147 priority patent/US6835750B1/en
Assigned to ACCERA, INC. reassignment ACCERA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HENDERSON, SAMUEL T.
Priority to US11/021,920 priority patent/US8445535B1/en
Priority to US11/331,673 priority patent/US20060122270A1/en
Priority to US11/611,114 priority patent/US20070179197A1/en
Priority to US12/064,850 priority patent/US8124589B2/en
Priority to US11/771,431 priority patent/US20080009467A1/en
Assigned to ACCERA, INC. reassignment ACCERA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HENDERSON, SAMUEL T
Priority to US12/821,401 priority patent/US20100261791A1/en
Priority to US13/445,679 priority patent/US8426468B2/en
Priority to US13/859,608 priority patent/US9603823B2/en
Priority to US15/465,171 priority patent/US10111849B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to the field of therapeutic agents for the treatment of Alzheimer's Disease, and other diseases associated with reduced neuronal metabolism.
  • AD Alzheimer's Disease
  • Early-onset AD is rare, strikes susceptible individuals as early as the third decade, and is frequently associated with mutations in a small set of genes.
  • Late onset AD is common, strikes in the seventh or eighth decade, and is a multifactorial disease with many genetic risk factors.
  • Late-onset AD is the leading cause of dementia in persons over the age of 65.
  • An estimated 7-10% of the American population over 65, and up to 40% of the American population greater than 80 years of age is afflicted with AD (McKhann et al., 1984; Evans et al. 1989).
  • patients experience loss of memory and orientation.
  • AD Alzheimer's disease
  • Aricept® and Cognex® are acetylcholinesterase inhibitors. These drugs do not address the underlying pathology of AD. They merely enhance the effectiveness of those nerve cells still able to function. Since the disease continues, the benefits of these treatments are slight.
  • AD Alzheimer's disease
  • PS1 presenilin1
  • PS2 presenilin2
  • APP amyloid precursor protein
  • the presenilin proteins may facilitate the cleavage of APP.
  • the A ⁇ peptide is amyloidagenic and under certain conditions will form insoluble fibrils.
  • the toxicity of A ⁇ peptide and fibrils remains controversial. In some cases A ⁇ has been shown to be neurotoxic, while others find it to be neurotrophic (for reviews see Selkoe, 1999).
  • the cause of early-onset AD is hypothesized to be accumulation of aggregated proteins in susceptible neurons. Mutations in APP are hypothesized to lead to direct accumulation of fibrillar A ⁇ , while mutations in PS1 or PS2 are proposed to lead to indirect accumulation of A ⁇ . How a variety of mutations in PS1 and PS2 lead to increased A ⁇ accumulation has not been resolved.
  • AD Alzheimer's disease
  • U.S. Pat. No. 5,385,915 “Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation”
  • patent U.S. Pat. No. 5,538,983 “Method of treating amyloidosis by modulation of calcium.”
  • Attempts to increase neuronal survival by use of nerve growth factors have dealt with either whole cell, gene or protein delivery, such as described in U.S. Pat. No. 5,650,148 “Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system”
  • U.S. Pat. No. 5,936,078 “DNA and protein for the diagnosis and treatment of Alzheimer's disease.”
  • AD Alzheimer's disease
  • late-onset AD is not associated with mutations in APP, PS1 or PS2, yet exhibits neuropathological lesions and symptoms that are similar to those found in early-onset AD. Since late-onset AD is the most common form, it will be referred to herein as AD, while early-onset AD will be referred to as such.
  • the similar neuropathology and outward symptoms of early-onset and late-onset AD have led to the “amyloid cascade hypothesis of AD”(Selkoe, 1994). This model holds that both early and late onset AD result from accumulation of toxic amyloid deposits.
  • amyloid accumulates rapidly, while in late onset, amyloid accumulates slowly.
  • Much of the research on prevention and treatment of AD has focused on inhibition of amyloid accumulation.
  • the amyloid cascade hypothesis remains controversial.
  • Amyloid deposits may be a marker for the disease and not the cause.
  • Translation of Dr. Alzheimer's original work on the neuropathology of AD relates that he did not favor the view that senile plaques were causative. He states “These changes are found in the basal ganglia, the medulla, the cerebellum and the spinal cord, although there are no plaques at all in those sites or only isolated ones.
  • lipid transport molecule apolipoprotein E apolipoprotein E
  • ApoE functions as a ligand in the process of receptor mediated internalization of lipid-rich lipoproteins. These lipoprotein complexes contain phosopholipids, triglycerides, cholesterol and lipoproteins.
  • apoE2 and E3 lipid transport molecule apolipoprotein E
  • ApoE4 is associated with an increased risk of AD, while apoE2 and E3 are not.
  • ApoE4 is the ancestral allele, it is most similar to the apoE found in chimpanzees and other primates, while the E2 and E3 alleles arose exclusively in the human lineage, (Hanlon and Rubinsztein, 1995). The changes in apoE were probably brought about by a change in diet in ancestral humans. The E2 and E3 alleles may have arisen in populations as an adaptation to agriculture (Corbo and Scacchi, 1999).
  • the metabolism of apoE4 in human circulation is different from the non-AD associated apoE3 allele (Gregg et al., 1986).
  • the E4 allele is associated with unusually high levels of circulating lipoproteins (Gregg et al., 1986).
  • the E4 allele results in decreased rates of VLDL clearance, which leads to higher levels of VLDL and LDL particles in the blood (Knouff, et al. 1999).
  • VLDL and LDL particles contain higher levels of triglycerides than HDL particles.
  • the increased levels of circulating VLDL in individuals carrying apoE4 is due to decreased fatty acid utilization caused by preferential binding of apoE4 to chylomicron and VLDL particles.
  • Prior art has suggested that apoE4 contributes to AD due to inefficient delivery of phospholipids to neurons (for review see Beffert et al., 1998). Yet, apoE4 also contributes to decreased triglyceride usage.
  • apoE plays a central role in the transportation and redistribution of cholesterol and lipids.
  • the importance of apoe in the brain is highlighted by the absence of other key plasma apolipoproteins such as apoA1 and apoB in the brain (Roheim et al., 1979).
  • ApoE mRNA is found predominantly in astrocytes in the CNS. Astrocytes function as neuronal support cells and can efficiently utilize fatty acids for energy. Since the brain lacks other apolipoproteins, it is uniquely dependent on apoE for lipid transport, including triglycerides.
  • apoe While prior art on apoe's role in AD has focused on phospholipid transport, apoe also delivers free fatty acids in the form of triglycerides to astrocytes. Fatty acids delivered by lipoproteins can be converted to ketone bodies by astrocytes for use as an alternative energy source to glucose.
  • AD Alzheimer's Disease is associated with decreased neuronal metabolism.
  • Blass and Zemcov proposed that AD results from a decreased metabolic rate in subpopulations of cholinergic neurons.
  • AD is not restricted to cholinergic systems, but involves many types of transmitter systems, and several discrete brain regions.
  • Positron-emission tomography has revealed poor glucose utilization in the brains of AD patients, and this disturbed metabolism can be detected well before clinical signs of dementia occur (Reiman et al., 1996; Messier and Gagnon, 1996; Hoyer, 1998).
  • somatostatin cells of the cortex in AD brain are smaller, and have reduced Golgi apparatus; both indicating decreased metabolic activity (for review see Swaab et al. 1998).
  • Measurements of the cerebral metabolic rates in healthy versus AD patients demonstrated a 20-40% reduction in glucose metabolism in AD patients (Hoyer, 1992). Reduced glucose metabolism results in critically low levels of ATP in AD patients. Also, the severity of decreased metabolism was found to correlate with senile plaque density (Meier-Ruge, et al. 1994).
  • Glucose is transported across the blood brain barrier and is used as a major fuel source in the adult brain. Consistent with the high level of glucose utilization, the brains of mammals are well supplied with receptors for insulin and IGF, especially in the areas of the cortex and hippocampus, which are important for learning and memory (Frolich et al., 1998). In patients diagnosed with AD, increased densities of insulin receptor were observed in many brain regions, yet the level of tyrosine kinase activity that normally is associated with the insulin receptor was decreased, both relative to age-matched controls (Frolich et al., 1998).
  • the increased density of receptors represents up-regulation of receptor levels to compensate for decreased receptor activity.
  • Activation of the insulin receptor is known to stimulate phosphatidylinositol-3 kinase (P13K).
  • P13K activity is reduced in AD patients (Jolles et al., 1992; Zubenko et al., 1999).
  • the density of the major glucose transporters in the brain, GLUT1 and GLUT3 were found to be 50% of age matched controls (Simpson and Davies 1994).
  • the disturbed glucose metabolism in AD has led to the suggestion that AD may be a form of insulin resistance in the brain, similar to type II diabetes (Hoyer, 1998).
  • Inhibition of insulin receptor activity can be exogenously induced in the brains of rats by intracerebroventricular injection of streptozotocin, a known inhibitor of the insulin receptor. These animals develop progressive defects in learning and memory (Lannert and Hoyer, 1998). While glucose utilization is impaired in brains of AD patients, use of the ketone bodies, beta-hydroxybutyrate and acteoacetate is unaffected (Ogawa et al. 1996).
  • AD neuronal metabolism in AD
  • Insulin stimulation of glucose uptake is impaired in the elderly, leading to decreased insulin action and increased insulin resistance (for review see Finch and Cohen, 1997).
  • mean plasma glucose is 10-30% higher in those over 65 than in younger subjects.
  • genetic risk factors for AD may result in slightly compromised neuronal metabolism in the brain.
  • These defects would only become apparent later in life when glucose metabolism becomes impaired, and thereby contribute to the development of AD.
  • the defects in glucose utilization are limited to the brain in AD, the liver is “unaware” of the state of the brain and does not mobilize fatty acids (see Brain Metabolism section below). Without ketone bodies to use as an energy source, the neurons of the AD patient brain slowly and inexorably starve to death.
  • AD patients Attempts to compensate for reduced cerebral metabolic rates in AD patients has met with some success.
  • Treatment of AD patients with high doses of glucose and insulin increases cognitive scores (Craft et al., 1996).
  • insulin is a polypeptide and must be transported across the blood brain barrier, delivery to the brain is complicated. Therefore, insulin is administered systemically. Large dose of insulin in the blood stream can lead to hyperinsulinemia, which will cause irregularities in other tissues. Both of these shortcomings make this type of therapy difficult and rife with complications. Accordingly, there remains a need for an agent that may increase the cerebral metabolic rate and subsequently the cognitive abilities of a patient suffering from Alzheimer's disease.
  • the brain has a very high metabolic rate. For example, it uses 20 percent of the total oxygen consumed in a resting state. Large amounts of ATP are required by neurons of the brain for general cellular functions, maintenance of an electric potential, synthesis of neurotransmitters and synaptic remodeling.
  • Current models propose that under normal physiologic conditions, neurons of the adult human brain depend solely on glucose for energy. Since neurons lack glycogen stores, the brain depends on a continuous supply of glucose from the blood for proper function. Neurons are very specialized and can only efficiently metabolize a few substrates, such as glucose and ketone bodies. This limited metabolic ability makes brain neurons especially vulnerable to changes in energy substrates. Hence, sudden interruption of glucose delivery to the brain results in neuronal damage. Yet, if glucose levels drop gradually, such as during fasting, neurons will begin to metabolize ketone bodies instead of glucose and no neuronal damage will occur.
  • Neuronal support cells are much more metabolically diverse and can metabolize many substrates, in particular, glial cells are able to utilize fatty acids for cellular respiration. Neurons of the brain cannot efficiently oxidize fatty acids and hence rely on other cells, such as liver cells and astrocytes to oxidize fatty acids and produce ketone bodies. Ketone bodies are produced from the incomplete oxidation of fatty acids and are used to distribute energy throughout the body when glucose levels are low. In a normal Western diet, rich in carbohydrates, insulin levels are high and fatty acids are not utilized for fuel, hence blood ketone body levels are very low, and fat is stored and not used. Such a scenario explains the prevalence of obesity.
  • ketone bodies for fuel.
  • the partial oxidation of fatty acids gives rise to D-beta-hydroxybutyrate (D-3-hydroxybutyrate) and acetoacetate, which together with acetone are collectively called ketone bodies.
  • Neonatal mammals are dependent upon milk for development.
  • the major carbon source in milk is fat (carbohydrates make up less then 12% of the caloric content of milk).
  • the fatty acids in milk are oxidized to give rise to ketone bodies, which then diffuse into the blood to provide an energy source for development. Numerous studies have shown that the preferred substrates for respiration in the developing mammalian neonatal brain are ketone bodies.
  • the body normally produces small amounts of ketone bodies. However, because they are rapidly utilized, the concentration of ketone bodies in the blood is very low. Blood ketone body concentrations rise on a low carbohydrate diet, during periods of fasting, and in diabetics. In a low carbohydrate diet, blood glucose levels are low, and pancreatic insulin secretion is not stimulated. This triggers the oxidation of fatty acids for use as a fuel source when glucose is limiting. Similarly, during fasting or starvation, liver glycogen stores are quickly depleted, and fat is mobilized in the form of ketone bodies. Since both a low carbohydrate diet and fasting do not result in a rapid drop of blood glucose levels, the body has time to increase blood ketone levels.
  • ketone bodies provide the brain with an alternative fuel source, and no cellular damage occurs. Since the brain has such high energy demands, the liver oxidizes large amounts of fatty acids until the body becomes literally saturated in ketone bodies. Therefore, when an insufficient source of ketone bodies is coupled with poor glucose utilization severe damage to neurons results. Since glial cells are able to utilize a large variety of substrates they are less susceptible to defects in glucose metabolism than are neurons. This is consistent with the observation that glial cells do not degenerate and die in AD (Mattson, 1998).
  • AD Alzheimer's Disease
  • neurons of the brain are unable to utilize glucose and begin to starve to death. Since the defects are limited to the brain and peripheral glucose metabolism is normal, the body does not increase production of ketone bodies, therefore neurons of the brain slowly starve to death. Accordingly, there remains a need for an energy source for brain cells that exhibit compromised glucose metabolism in AD patients. Compromised glucose metabolism is a hallmark of AD; hence administration of such an agent will prove beneficial to those suffering from AD.
  • MCT long chain triglycerides
  • MCFA medium chain fatty acids
  • MCT and MCFA are liquid at room temperature.
  • MCT are highly ionized at physiological pH, thus they have much greater solubility in aqueous solutions than LCT.
  • the enhanced solubility and small size of MCT also increases the rate at which fine emulsion particles are formed.
  • MCFA In the liver the major metabolic fate of MCFA is oxidation. The fate of LCFA in the liver is dependent on the metabolic state of the organism. LCFA are transported into the mitochondria for oxidation using camitine palmitoyltransferase I. When conditions favor fat storage, malonyl-CoA is produced as an intermediate in lipogenesis. Malonyl-CoA allosterically inhibits carnitine palmitoyltransferase I, and thereby inhibits LCFA transport into the mitochondria. This feedback mechanism prevents futile cycles of lipolysis and lipogenesis. MCFA are, to large extent, immune to the regulations that control the oxidation of LCFA.
  • MCFA enter the mitochondria largely without the use of carnitine palmitoyltransferase I, therefore MCFA by-pass this regulatory step and are oxidized regardless of the metabolic state of the organism. Importantly, since MCFA enter the liver rapidly and are quickly oxidized, large amounts of ketone bodies are readily produced from MCFA.
  • the present invention provides a method of treating or preventing dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of medium chain triglycerides to a patient in need thereof.
  • Administration may be oral or intravenous.
  • the medium chain triglycerides may be emulsified, and may be coadministered with L-carnitine or a derivative of L-carnitine.
  • the present invention also provides a method of treating or preventing dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of free fatty acids derived from medium chain triglycerides to a patient in need thereof.
  • the present invention also provides a method of treating or preventing dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of a medium chain triglyceride prodrug to a patient in need thereof.
  • the present invention also provides a method of treating or preventing dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of a therapeutic agent which induces utilization of fatty acids and development of ketosis to a patient in need thereof.
  • the present invention further provides therapeutic agents for the treatment or prevention of dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism.
  • MCT medium chain triglycerides
  • a diet rich in MCT results in high blood ketone levels.
  • High blood ketone levels will provide an energy source for brain cells that have compromised glucose metabolism via the rapid oxidation of MCFA to ketone bodies.
  • the background of this invention supports the present invention in the following ways.
  • Neurons of the brain can use both glucose and ketone bodies for respiration.
  • the neurons of Alzheimer's Disease patients have well documented defects in glucose metabolism.
  • Known genetic risk factors for Alzheimer's Disease are associated with lipid and cholesterol transport, suggesting defects in triglyceride usage may underlie susceptibility to Alzheimer's Disease.
  • a diet rich in MCT will lead to increased levels of blood ketone bodies and thereby provide energy to starving brain neurons. Hence, supplementation of Alzheimer's Disease patients with MCT will restore neuronal metabolism.
  • the present invention provides a method of treating or preventing dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of medium chain triglycerides to a patient in need thereof.
  • an effective amount is an amount effective to either (1) reduce the symptoms of the disease sought to be treated or (2) induce a pharmacological change relevant to treating the disease sought to be treated.
  • an effective amount includes an amount effective to: increase cognitive scores; slow the progression of dementia; or increase the life expectancy of the affected patient.
  • medium chain triglycerides of this invention are represented by the following formula:
  • R1, R2 and R3 are fatty acids having 5-12 carbons in the carbon backbone.
  • the structured lipids of this invention may be prepared by any process known in the art, such as direct esterification, rearrangement, fractionation, transesterification, or the like.
  • the lipids may be prepared by the rearrangement of a vegetable oil such as coconut oil.
  • the method comprises the use of MCTs wherein R1, R2, and R3 are fatty acids containing a six-carbon backbone (tri-C6:0).
  • Tri-C6:0 MCT are absorbed very rapidly by the gastrointestinal track in a number of model systems (Odle 1997). The high rate of absorption results in rapid perfusion of the liver, and a potent ketogenic response.
  • utilization of tri-C6:0 MCT can be increased by emulsification. Emulsification of lipids increases the surface area for action by lipases, resulting in more rapid hydrolysis. Methods for emulsification of these triglycerides are well known to those skilled in the art.
  • the invention provides a method of treating or preventing dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising administering an effective amount of free fatty acids, which may be derived from medium chain triglycerides, to a patient in need thereof.
  • free fatty acids are referred to herein as free medium chain fatty acids, or free fatty acids.
  • the invention comprises the coadministration of emulsified tri-C6:0 MCT and L-camitine or a derivative of Lcamitine. Slight increases in MCFA oxidation have been noted when MCT are combined with L-camitine (Odle, 1997). Thus in the present invention emulsified triC6:0 MCT are combined with L-camitine at doses required to increase the utilization of said MCT.
  • the dosage of L-camitine and MCT will vary according to the condition of the host, method of delivery, and other factors known to those skilled in the art, and will be of sufficient quantity to raise blood ketone levels to a degree required to treat and prevent Alzheimer's Disease.
  • L-camitine which may be used in the present invention include but are not limited to decanoylcamitine, hexanoylcamitine, caproylcarnitine, lauroylcarnitine, octanoylcatnitine, stearoylcarnitine, myristoylcamitine, acetyl-L-carnitine, O-Acetyl-L-carnitine, and palmitoyl-L-carnitine.
  • Therapeutically effective amounts of the therapeutic agents can be any amount or dose sufficient to bring about the desired anti-dementia effect and depend, in part, on the severity and stage of the condition, the size and condition of the patient, as well as other factors readily known to those skilled in the art.
  • the dosages can be given as a single dose, or as several doses, for example, divided over the course of several weeks.
  • the MCT's or fatty acids are administered orally. In another embodiment, the MCT's are administered intravenously. Oral administration of MCT's and preparations intravenous MCT solutions are well known to those skilled in the art.
  • Hyperketonemia results in ketone bodies being utilized for energy in the brain even in the presence of glucose. Additionally, hyperketonemia results in a substantial (39%) increase in cerebral blood flow (Hasselbalch et al. 1996). Hyperketonemia has been reported to reduce cognitive dysfunction associated with systemic hypoglycemia in normal humans (Veneman et al. 1994). Please note that systemic hypoglycemia is distinct from the local defects in glucose metabolism that occur in AD.
  • the invention provides the subject compounds in the form of one or more prodrugs, which can be metabolically converted to the subject compounds by the recipient host.
  • a prodrug is a compound that exhibits pharmacological activity after undergoing a chemical transformation in the body.
  • the said prodrugs will be administered in a dosage required to increase blood ketone bodies to a level required to treat and prevent the occurrence of Alzheimer's Disease.
  • prodrug bonds may be hydrolyzable, such as esters or anhydrides, or enzymatically biodegradable, such as amides.
  • This invention also provides a therapeutic agent for the treatment or prevention of dementia of Alzheimer's type, or other loss of cognitive function caused by reduced neuronal metabolism, comprising medium chain triglycerides.
  • the therapeutic agent is provided in administratively convenient formulations of the compositions including dosage units incorporated into a variety of containers. Dosages of the MCT are preferably administered in an effective amount, in order to produce ketone body concentrations sufficient to increase the cognitive ability of patients afflicted with AD or other states of reduced neuronal metabolism.
  • ketone body D-beta-hydroxybutyrate blood levels are raised to about 1-10 mM or as measured by urinary excretion in the range of about 5 mg/dL to about 160 mg/dL, although variations will necessarily occur depending on the formulation and host, for example.
  • Effective amount dosages of other MCTs will be apparent to those skilled in the art.
  • Convenient unit dosage containers and/or formulations include tablets, capsules, lozenges, troches, hard candies, nutritional bars, nutritional drinks, metered sprays, creams, and suppositories, among others.
  • the compositions may be combined with a pharmaceutically acceptable excipient such as gelatin, an oil, and/or other pharmaceutically active agent(s).
  • compositions may be advantageously combined and/or used in combination with other therapeutic or prophylactic agents, different from the subject compounds.
  • administration in conjunction with the subject compositions enhances the efficacy of such agents.
  • the compounds may be advantageously used in conjunction with antioxidants, compounds that enhance the efficiency of glucose utilization, and mixtures thereof, (see e.g. Goodman et al. 1996).
  • the human subject is intravenously infused with MCT, MCFA (medium chain fatty acids) and/or ketone bodies directly, to a level required to treat and prevent the occurrence of Alzheimer's Disease.
  • MCT massive chain fatty acids
  • MCFA medium chain fatty acids
  • ketone bodies directly, to a level required to treat and prevent the occurrence of Alzheimer's Disease.
  • Preparation of intravenous lipid, and ketone body solutions is well known to those skilled in the art.
  • the invention provides a formulation comprising a mixture of MCT and carnitine to provide elevated blood ketone levels.
  • the nature of such formulations will depend on the duration and route of administration. Such formulations will be in the range of 0.5 g/kg/day to 10 g/kg/day of MCT and 0.5 mg/kg/day to 10 mg/kg/day of camitine or its derivatives,. Variations will necessarily occur depending on the formulation and/or host, for example.
  • a particularly preferred formulation comprises a range of 10-500 g of emulsified MCT combined with 10-2000 mg of carnitine.
  • An even more preferred formulation comprises 50 g MCT (95% triC8:0) emulsified with 50 g of mono- and di-glycerides combined with 500 mg of L-carnitine.
  • Such a formulation is well tolerated and induces hyperketonemia for 3-4 hours in healthy human subjects.
  • the invention provides the recipient with a therapeutic agent which enhances endogenous fatty acid metabolism by the recipient.
  • the said therapeutic agent will be administered in a dosage required to increase blood ketone bodies to a level required to treat and prevent the occurrence of Alzheimer's Disease.
  • Ketone bodies are produced continuously by oxidation of fatty acids in tissues that are capable of such oxidation.
  • the major organ for fatty acid oxidation is the liver. Under normal physiological conditions ketone bodies are rapidly utilized and cleared from the blood. Under some conditions, such as starvation or low carbohydrate diet, ketone bodies are produced in excess and accumulate in the blood stream.
  • MCT medium chain triglycerides
  • AD Alzheimer's Disease
  • MCT may prove more effective when combined with insulin sensitizing agents such as vanadyl sulfate, chromium picolinate, and vitamin E.
  • agents may function to increase glucose utilization in compromised neurons and work synergistically with hyperketonemia.
  • MCT can be combined with compounds that increase the rates of fatty acid utilization such as L-camitine and its derivatives. Mixtures of such compounds may synergistically increase levels of circulating ketone bodies.
  • Nutritional drinks are prepared using the following ingredients: emulsified MCT 100 gr/drink, L-camitine 1 gram/drink, mix of daily vitamins at recommended daily levels, and a variety of flavorings.
  • Additional formulations can be in the form of Ready to Drink Beverage, Powdered Beverages, Nutritional drinks, Food Bars, and the like. Formulations for such are clear to those skilled in the art.
  • Ready to Drink Beverages are prepared using the following ingredients: emulsified MCT 5-100 g/drink, L-camitine 250-1000 mg/drink, and a variety of flavorings and other ingredients used to increased palatability, stability, etc.
  • MCT may be prepared in a dried form, useful for food bars and powdered beverage preparations.
  • a powdered beverage may be formed from the following components: dried emulsified MCT 10-50 g, L-carnitine 250-500 mg, sucrose 8-15 g, maltodextrin 1-5 g, flavorings 0-1 g.
  • a food bar would consist of: dried emulsified MCT 10-50 g, L-carnitine 250-500 mg, glycerin 1-5 g, corn syrup solids 5-25 g, cocoa 2-7 g, coating 15-25 g.
  • Hard gelatin capsules are prepared using the following ingredients: MCT 0.1-1000 mg/capsule, L-carnitine 250-500 mg/capsule, Starch, NF 0-600 mg/capsule; Starch flowable powder 0-600 mg/capsule; Silicone fluid 350 centistokes 0-20 mg/capsule. The ingredients are mixed, passed through a sieve, and filled into capsules.
  • Tablets are prepared using the following ingredients: MCT 0.11000 mg/tablet; L-carnitine 250-500 mg/tablet; Microcrystalline cellulose 20-300 mg/tablet; Starch 0-50 mg/tablet; Magnesium stearate or stearate acid 0-15 mg/tablet; Silicon dioxide, fumed 0-400 mg/tablet; silicon dioxide, colloidal 0-1 mg/tablet, and lactose 0-100 mg/tablet. The ingredients are blended and compressed to form tablets.
  • Suspensions are prepared using the following ingredients: 0.1-1000 mg MCT; 250-500 mg L-camitine; Sodium carboxymethyl cellulose 50-700 mg/5 ml; Sodium benzoate 0-10 mg/5 ml; Purified water 5 ml; and flavor and color agents as needed.
  • a parenteral composition is prepared by stirring 1.5% by weight of MCT and L-carnitine in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US09/845,741 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism Abandoned US20020006959A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US09/845,741 US20020006959A1 (en) 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
US10/152,147 US6835750B1 (en) 2000-05-01 2002-05-20 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US11/021,920 US8445535B1 (en) 2000-05-01 2004-12-22 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US11/331,673 US20060122270A1 (en) 2000-05-01 2006-01-13 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US11/611,114 US20070179197A1 (en) 2000-05-01 2006-12-14 Compositions and methods for improving or preserving brain function
US12/064,850 US8124589B2 (en) 2000-05-01 2007-04-03 Use of ketogenic compounds for treatment of age-associated memory impairment
US11/771,431 US20080009467A1 (en) 2000-05-01 2007-06-29 Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US12/821,401 US20100261791A1 (en) 2000-05-01 2010-06-23 Compositions and Methods for Improving or Preserving Brain Function
US13/445,679 US8426468B2 (en) 2000-05-01 2012-04-12 Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism
US13/859,608 US9603823B2 (en) 2000-05-01 2013-04-09 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US15/465,171 US10111849B2 (en) 2000-05-01 2017-03-21 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20098000P 2000-05-01 2000-05-01
US09/845,741 US20020006959A1 (en) 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/152,147 Continuation-In-Part US6835750B1 (en) 2000-05-01 2002-05-20 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US11/331,673 Continuation US20060122270A1 (en) 2000-05-01 2006-01-13 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism

Publications (1)

Publication Number Publication Date
US20020006959A1 true US20020006959A1 (en) 2002-01-17

Family

ID=22743976

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/845,741 Abandoned US20020006959A1 (en) 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
US11/331,673 Abandoned US20060122270A1 (en) 2000-05-01 2006-01-13 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US13/445,679 Expired - Fee Related US8426468B2 (en) 2000-05-01 2012-04-12 Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/331,673 Abandoned US20060122270A1 (en) 2000-05-01 2006-01-13 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US13/445,679 Expired - Fee Related US8426468B2 (en) 2000-05-01 2012-04-12 Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism

Country Status (10)

Country Link
US (3) US20020006959A1 (enrdf_load_stackoverflow)
EP (3) EP2319508A1 (enrdf_load_stackoverflow)
JP (2) JP2003531857A (enrdf_load_stackoverflow)
AT (1) ATE425750T1 (enrdf_load_stackoverflow)
AU (1) AU2001257451A1 (enrdf_load_stackoverflow)
DE (1) DE60138019D1 (enrdf_load_stackoverflow)
DK (1) DK1292294T3 (enrdf_load_stackoverflow)
ES (2) ES2752800T3 (enrdf_load_stackoverflow)
PT (1) PT1292294E (enrdf_load_stackoverflow)
WO (1) WO2001082928A1 (enrdf_load_stackoverflow)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266872A1 (en) * 1997-03-17 2004-12-30 Btg International Limited Therapeutic compositions
US20060189545A1 (en) * 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
US20070243211A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof
WO2007115282A3 (en) * 2006-04-03 2007-12-21 Accera Inc Use of ketogenic compounds for treatment of age-associated memory impairment
US20080311100A1 (en) * 2005-05-16 2008-12-18 Laboratoires Inneov Treatment of Keratinous Dryness With Glycerides
US20100003730A1 (en) * 2008-07-03 2010-01-07 Accera, Inc. Enzymatic Synthesis of Acetoacetate Esters and Derivatives
US20100041751A1 (en) * 2005-06-20 2010-02-18 Accera, Inc. Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency
EP2150265A4 (en) * 2007-05-14 2010-06-09 Neuera Pharmaceuticals Inc INHIBITORS OF ACETYL-COA-CARBOXYLASE FOR THE TREATMENT OF NEURONAL HYPOMETABOLISM
US20110178032A1 (en) * 2008-07-03 2011-07-21 Accera, Inc. Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8426468B2 (en) 2000-05-01 2013-04-23 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism
US8445535B1 (en) 2000-05-01 2013-05-21 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20140377245A9 (en) * 2011-08-31 2014-12-25 St. Jude Children's Research Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
US9175345B2 (en) 2007-07-31 2015-11-03 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20150320874A1 (en) * 2007-03-13 2015-11-12 Jds Therapeutics, Llc Methods and compositions for the sustained release of chromium
US9211275B2 (en) 2008-01-04 2015-12-15 Isis Innovation Ltd. Ketone bodies and ketone body esters as blood lipid lowering agents
US20160354335A1 (en) * 2014-02-11 2016-12-08 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
US9579302B2 (en) 2012-11-05 2017-02-28 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
WO2017093449A1 (en) 2015-12-04 2017-06-08 Nestec S.A. Medium chain triglyceride compositions
US10051880B2 (en) 2008-08-21 2018-08-21 Oxford University Innovation Limited Hydroxybutyrate ester and medical use thereof
US10660958B2 (en) 2010-02-22 2020-05-26 Tdeltas Limited Nutritional composition
US10821062B2 (en) 2013-03-12 2020-11-03 Tdeltas Limited Compound for use in protecting skin
US11230722B2 (en) 2003-06-03 2022-01-25 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20220202760A1 (en) * 2004-05-12 2022-06-30 Btg International Limited Cns modulators
US11566268B2 (en) 2013-03-14 2023-01-31 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
GB0306394D0 (en) 2003-03-20 2003-04-23 Univ Nottingham Carnitine retention
US7485743B2 (en) 2004-07-20 2009-02-03 Btg International Limited Oligomeric ketone compounds
EP1796658B1 (en) * 2004-09-21 2016-03-30 BTG International Limited Dopaminergic mimetics
US7702343B2 (en) * 2005-04-04 2010-04-20 Qualcomm Incorporated Efficient gap allocation for cell measurements in asynchronous communication networks
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
HUE037129T2 (hu) * 2005-12-15 2018-08-28 Nestec Sa Kompozíciók és eljárások agyi funkció megõrzésére
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2144618B2 (en) 2007-03-28 2024-11-20 Aker Biomarine Antarctic As Bioeffective krill oil compositions
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
PT2170316E (pt) 2007-06-26 2014-01-30 Nutricia Nv Melhoramento de memória em indivíduos com exame de estado mini mental de 24-26
PL2222311T3 (pl) 2007-12-20 2013-08-30 Nutricia Nv Ciekły produkt zawierający nukleotydy/nukleozydy
SG195572A1 (en) * 2008-07-18 2013-12-30 Dart Neuroscience Cayman Ltd Methods and systems for evaluating memory agents
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
CA2785714C (en) * 2009-12-30 2016-01-26 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
US8349376B1 (en) * 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
CA2894456C (en) 2012-12-13 2022-06-28 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
ES2774321T3 (es) 2013-11-14 2020-07-20 Univ Queensland Trastornos neurodegenerativos y métodos de tratamiento y diagnóstico de los mismos
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
PL3229790T3 (pl) 2014-12-08 2020-04-30 Société des Produits Nestlé S.A. Kompozycje zawierające triglicerydy o średniej długości łańcucha do stosowania w leczeniu padaczki
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
CN107580457A (zh) 2015-02-11 2018-01-12 阿克海洋生物南极股份公司 脂质组合物
AU2016363511A1 (en) * 2015-12-04 2018-05-10 Société des Produits Nestlé S.A. Method for improving cognition
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10736548B2 (en) * 2016-05-18 2020-08-11 Invoy Holdings, Inc. Ketone measurement system for monitoring medical conditions
CA3026152A1 (en) 2016-06-08 2017-12-14 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP7246843B2 (ja) * 2016-08-26 2023-03-28 日油株式会社 スポーツ飲料
KR102419759B1 (ko) 2017-03-15 2022-07-12 세레신 인코포레이티드 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
EP3765002B1 (en) 2018-03-15 2025-03-05 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
EP3934630A4 (en) * 2019-03-04 2022-11-23 Cerecin Inc. MEDIUM CHAIN TRIGLYCERIDE FORMULATIONS WITH IMPROVED BIOAVAILABILITY AND RELATED METHODS
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
WO2022018094A1 (en) * 2020-07-23 2022-01-27 Société des Produits Nestlé S.A. Mct formulations for improving cognitive functions and methods of making and using such formulations
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CA3196329A1 (en) * 2020-10-09 2022-04-14 Cerecin Inc. Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407821A (en) * 1980-09-24 1983-10-04 Roussel Uclaf Lipidic compositions for use in dietetics, reanimation and therapeutics
US5391375A (en) * 1988-12-22 1995-02-21 Lts Lohmann Therapie-Systeme Gmbh & Co., Kg Transdermal therapeutical system with physostigmine as active component and process for the production thereof
US5504072A (en) * 1993-10-08 1996-04-02 Sandoz Nutrition Ltd. Enteral nutritional composition having balanced amino acid profile
US5925684A (en) * 1996-03-11 1999-07-20 Basf Aktiengesellschaft Stable carotenoid emulsions suitable for parenteral administration
US5980939A (en) * 1996-07-26 1999-11-09 Chong Kun Dang Corp. Cyclosporin-containing pharmaceutical composition
US6395306B1 (en) * 1998-09-14 2002-05-28 Pan Pacific Pharmaceuticals, Inc. Bee venom protein and gene encoding same

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766145A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766146A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) * 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) * 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
SE8803141L (sv) 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
IT1240775B (it) 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
DK0531306T3 (da) 1990-04-26 1995-05-29 Procter & Gamble Shorteningsammensætninger indeholdende polyolfedtsyrepolyestere
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
GB9113484D0 (en) 1991-06-21 1991-08-07 Unilever Plc Cosmetic composition
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE69333461T2 (de) * 1992-10-13 2005-03-24 Duke University VERFAHREN ZUM nachweis der Alzheimer Krankheit
JP3486778B2 (ja) * 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US5420335A (en) 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5691325A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
EP2327404A1 (en) 1994-11-08 2011-06-01 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6319498B1 (en) 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
IT1284650B1 (it) 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
ES2530753T3 (es) * 1997-03-17 2015-03-05 Btg Int Ltd Composiciones terapéuticas que comprenden cuerpos cetónicos y precursores de los mismos
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
JP2002510604A (ja) 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
JP2002521330A (ja) 1998-07-22 2002-07-16 メタボリックス，インコーポレイテッド ３−ヒドロキシアルカン酸オリゴマーの栄養的および治療的使用
ES2283133T3 (es) * 1998-09-15 2007-10-16 Btg International Limited Composiciones terapeuticas (ii).
GB9908202D0 (en) 1999-04-12 1999-06-02 Unilever Plc Cosmetic compositions
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
PT1292294E (pt) 2000-05-01 2009-06-01 Accera Inc Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer
DE20012857U1 (de) * 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gmbh, Berneck Diätetisches Lebensmittel zum Fettabbau
US6667397B2 (en) 2000-08-25 2003-12-23 Eastman Chemical Company Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom
GB2368011A (en) 2000-10-17 2002-04-24 Unilever Plc Fatty acid esters of maltose and uses thereof
US20020103139A1 (en) * 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
JP2004517109A (ja) 2000-12-30 2004-06-10 エルジー ハウスホールド アンド ヘルスケア カンパニー．， リミテッド． グルコースアシル化誘導体またはシュークロースアシル化誘導体を含有する皮膚美白剤｛Ｃｏｓｍｅｔｉｃｆｏｒｓｋｉｎｗｈｉｔｅｎｉｎｇｃｏｎｔａｉｎｉｎｇａｃｙｌｓｕｂｓｔｉｔｕｔｅｄｄｅｒｉｖａｔｉｖｅｓｏｆｇｌｕｃｏｓｅｏｒｓｕｃｒｏｓｅ｝
WO2002098398A1 (en) * 2001-06-07 2002-12-12 Eisai Co., Ltd. Methods for preventing and treating diseases and conditions associated with cellular stress
WO2003028631A2 (en) * 2001-09-21 2003-04-10 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
US7320806B2 (en) * 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
US6884454B2 (en) 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1605950A4 (en) 2003-03-06 2008-01-09 Accera Inc NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS
EP1648952B1 (en) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
US20060252775A1 (en) 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
HUE037129T2 (hu) 2005-12-15 2018-08-28 Nestec Sa Kompozíciók és eljárások agyi funkció megõrzésére
JP2009532496A (ja) * 2006-04-03 2009-09-10 アクセラ・インコーポレーテッド 加齢に伴う記憶障害を治療するためのケト原性化合物の使用
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407821A (en) * 1980-09-24 1983-10-04 Roussel Uclaf Lipidic compositions for use in dietetics, reanimation and therapeutics
US5391375A (en) * 1988-12-22 1995-02-21 Lts Lohmann Therapie-Systeme Gmbh & Co., Kg Transdermal therapeutical system with physostigmine as active component and process for the production thereof
US5504072A (en) * 1993-10-08 1996-04-02 Sandoz Nutrition Ltd. Enteral nutritional composition having balanced amino acid profile
US5504072B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having balanced amino acid profile
US5925684A (en) * 1996-03-11 1999-07-20 Basf Aktiengesellschaft Stable carotenoid emulsions suitable for parenteral administration
US5980939A (en) * 1996-07-26 1999-11-09 Chong Kun Dang Corp. Cyclosporin-containing pharmaceutical composition
US6395306B1 (en) * 1998-09-14 2002-05-28 Pan Pacific Pharmaceuticals, Inc. Bee venom protein and gene encoding same

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101653B2 (en) 1997-03-17 2012-01-24 Btg International Limited Therapeutic compositions
US20040266872A1 (en) * 1997-03-17 2004-12-30 Btg International Limited Therapeutic compositions
US10111849B2 (en) 2000-05-01 2018-10-30 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8124589B2 (en) * 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20080287372A1 (en) * 2000-05-01 2008-11-20 Accera, Inc. Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment
US9603823B2 (en) 2000-05-01 2017-03-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8445535B1 (en) 2000-05-01 2013-05-21 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8426468B2 (en) 2000-05-01 2013-04-23 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism
US20060189545A1 (en) * 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
US11230722B2 (en) 2003-06-03 2022-01-25 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20220202760A1 (en) * 2004-05-12 2022-06-30 Btg International Limited Cns modulators
US20080311100A1 (en) * 2005-05-16 2008-12-18 Laboratoires Inneov Treatment of Keratinous Dryness With Glycerides
US20100041751A1 (en) * 2005-06-20 2010-02-18 Accera, Inc. Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency
EP1954262A4 (en) * 2005-11-07 2012-05-02 Russell M Jaffe COMPOSITIONS FOR THE REGULATION OF METABOLISM AND APPLICATION METHODS
US20070243211A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof
US8748400B2 (en) 2006-04-03 2014-06-10 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
WO2007115282A3 (en) * 2006-04-03 2007-12-21 Accera Inc Use of ketogenic compounds for treatment of age-associated memory impairment
US9597404B2 (en) * 2007-03-13 2017-03-21 Jds Therapeutics, Llc Methods and compositions for sustained release of chromium
US20150320874A1 (en) * 2007-03-13 2015-11-12 Jds Therapeutics, Llc Methods and compositions for the sustained release of chromium
EP2150265A4 (en) * 2007-05-14 2010-06-09 Neuera Pharmaceuticals Inc INHIBITORS OF ACETYL-COA-CARBOXYLASE FOR THE TREATMENT OF NEURONAL HYPOMETABOLISM
US10105338B2 (en) 2007-07-31 2018-10-23 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US9175345B2 (en) 2007-07-31 2015-11-03 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US10154982B2 (en) 2008-01-04 2018-12-18 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US11311509B2 (en) 2008-01-04 2022-04-26 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US9211275B2 (en) 2008-01-04 2015-12-15 Isis Innovation Ltd. Ketone bodies and ketone body esters as blood lipid lowering agents
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US20100003730A1 (en) * 2008-07-03 2010-01-07 Accera, Inc. Enzymatic Synthesis of Acetoacetate Esters and Derivatives
US20110178032A1 (en) * 2008-07-03 2011-07-21 Accera, Inc. Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders
US10051880B2 (en) 2008-08-21 2018-08-21 Oxford University Innovation Limited Hydroxybutyrate ester and medical use thereof
US11571479B2 (en) 2010-02-22 2023-02-07 Tdeltas Nutritional composition
US10660958B2 (en) 2010-02-22 2020-05-26 Tdeltas Limited Nutritional composition
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US9840727B2 (en) 2011-08-31 2017-12-12 St. Jude Children's Research Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
US9399791B2 (en) * 2011-08-31 2016-07-26 St. Jude Children's Research Hospital Methods of treating alzheimer's disease by administration of protective protein/cathepsin A
US20140377245A9 (en) * 2011-08-31 2014-12-25 St. Jude Children's Research Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
US10533208B2 (en) 2011-08-31 2020-01-14 St. Jude Children's Research Hospital Methods of treating dementia associated with Alzheimer's disease with protective protein/cathepsin A (PPCA)
US8545896B2 (en) 2011-09-29 2013-10-01 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US10478415B2 (en) 2012-11-05 2019-11-19 Tdeltas Limited Ketone bodies to protect tissues from damage by ionizing radiation
US9579302B2 (en) 2012-11-05 2017-02-28 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
US11234953B2 (en) 2012-11-05 2022-02-01 Tdeltas Limited Ketone bodies to protect tissues from damage by ionizing radiation
US10821062B2 (en) 2013-03-12 2020-11-03 Tdeltas Limited Compound for use in protecting skin
US12377032B2 (en) 2013-03-12 2025-08-05 Tdeltas Limited Compound for use in protecting skin
US11566268B2 (en) 2013-03-14 2023-01-31 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
US10905672B2 (en) * 2014-02-11 2021-02-02 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
US20160354335A1 (en) * 2014-02-11 2016-12-08 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
WO2017093449A1 (en) 2015-12-04 2017-06-08 Nestec S.A. Medium chain triglyceride compositions
US11857527B2 (en) 2015-12-04 2024-01-02 Societe Des Produits Nestle S.A. Medium chain triglyceride compositions
EP3383383B1 (en) * 2015-12-04 2024-07-17 Société des Produits Nestlé S.A. Medium chain triglyceride compositions for use in the treatment or prevention of glucose transporter type 1 deficiency syndrome, and/or epilepsy
US12251367B2 (en) 2015-12-04 2025-03-18 Société des Produits Nestlé S.A. Medium chain triglyceride compositions

Also Published As

Publication number Publication date
EP1292294A1 (en) 2003-03-19
ES2752800T3 (es) 2020-04-06
JP2012188431A (ja) 2012-10-04
ATE425750T1 (de) 2009-04-15
WO2001082928A1 (en) 2001-11-08
WO2001082928A9 (en) 2006-06-15
JP5701245B2 (ja) 2015-04-15
AU2001257451A8 (en) 2006-11-09
EP2065041A1 (en) 2009-06-03
US8426468B2 (en) 2013-04-23
ES2323940T3 (es) 2009-07-28
JP2003531857A (ja) 2003-10-28
EP1292294B1 (en) 2009-03-18
PT1292294E (pt) 2009-06-01
AU2001257451A1 (en) 2001-11-12
EP2065041B1 (en) 2019-07-31
US20120196932A1 (en) 2012-08-02
EP1292294A4 (en) 2004-04-14
US20060122270A1 (en) 2006-06-08
DE60138019D1 (de) 2009-04-30
DK1292294T3 (da) 2009-06-22
EP2319508A1 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
US8426468B2 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism
US10111849B2 (en) Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) Compositions and methods for improving or preserving brain function
KR101634083B1 (ko) 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도
EP1773312B1 (en) Composition containing statins and omega-3 fatty acids
Lane et al. Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype
US20230364157A1 (en) Krill oil composition enriched in lpc-dha and lpc-epa
Uddin et al. Emerging therapeutic promise of ketogenic diet to attenuate neuropathological alterations in Alzheimer’s disease
JP2006519843A (ja) 新規化学物質及び代謝異常の治療におけるそれらの使用法
KR20110043648A (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
US20070225367A1 (en) Composition for beneficially influencing Alzheimer's disease and/or for Alzheimer's prophylaxis
US20100029759A1 (en) Composition useful for the treatment of type 2 diabetes
Jiménez et al. Insulin Resistance in Cystic Fibrosis: Management
HK1157580A (en) Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: ACCERA, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HENDERSON, SAMUEL T.;REEL/FRAME:013143/0653

Effective date: 20020719

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION